229 completed, 51 terminated, 24 recruiting, 15 unknown. 349 Phase 3, 33 Phase 2.
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-10-06 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 312 | 2026-09-01 | 2026-10-15 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds - Partial Epilepsy | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 20 | 2026-06-10 | 2026-10-09 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 333 | 2026-06-05 | 2026-10-26 |
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks - Focal Epilepsy | Phase 3 | Active not recruiting | Praxis Precision Medicines | 300 | 2026-01-29 | 2026-08-03 |
| LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS) | Phase 3 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2025-12-22 | 2026-01-12 |
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| Levetiracetam Three Times Daily in Epilepsy Levetiracetam - Epilepsy | Phase 3 | Recruiting | Waad Alkathiri | 120 | 2025-10-01 | 2026-03-24 |
| TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders L-serine, Maltodextrin (Placebo) - GRIN-related Disorders, GRIN1 | Phase 3 | Recruiting | Meyer Children's Hospital IRCCS | 40 | 2025-08-29 | 2026-01-29 |
| Effect of Different Anesthetic Drugs on Electrocorticography (ECOG). Fentanyl (IV), Ketamine (0.5 mg/kg) - Epilepsy, Brain Tumor | Phase 3 | Active not recruiting | Children's Cancer Hospital Egypt 57357 | 88 | 2025-08-18 | 2025-09-10 |
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety 1mg elsunersen, 0.5mg elsunersen - Epileptic Encephalopathy, SCN2A Encephalopathy | Phase 3 | Recruiting | Praxis Precision Medicines | 40 | 2025-08-13 | 2026-08-03 |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo - Developmental and Epileptic Encephalopathy 1 | Phase 3 | Active not recruiting | Praxis Precision Medicines | 160 | 2025-07-09 | 2026-08-04 |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome zorevunersen, Sham Comparator - Dravet Syndrome | Phase 3 | Active not recruiting | Stoke Therapeutics, Inc | 170 | 2025-06-04 | 2026-10-20 |
| An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Clemizole HCl, Placebo - Lennox Gastaut Syndrome | Phase 3 | Recruiting | Epygenix | 260 | 2025-04-09 | 2026-10-09 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) LP352 - Developmental and Epileptic Encephalopathy | Phase 3 | Enrolling by invitation | Longboard Pharmaceuticals | 324 | 2025-02-12 | 2026-10-14 |
| Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy | Phase 3 | Recruiting | UMC Utrecht | 50 | 2025-02-06 | 2026-06-25 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
| Lemborexant Treatment of Insomnia Linked to Epilepsy Lemborexant, Placebo - Epilepsy, Sleep | Phase 3 | Recruiting | University of Manitoba | 26 | 2024-10-29 | 2025-02-13 |
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) LP352, Placebo - Dravet Syndrome | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 108 | 2024-09-25 | 2026-10-27 |
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Active not recruiting | UCB Biopharma SRL | 70 | 2024-07-10 | 2026-08-27 |
Showing 20 of 349. Sign in to see all of them.
Seizures (124) · Epilepsies, Partial (68) · Epilepsies, Myoclonic (25) · Lennox Gastaut Syndrome (25) · Drug Resistant Epilepsy (18) · Spasms, Infantile (17) · Epilepsy, Generalized (11) · Epilepsy, Complex Partial (9) · Epilepsy, Tonic-Clonic (9) · Migraine Disorders (9) · Brain Diseases (7) · Epilepsy, Absence (6) · Epilepsy, Idiopathic Generalized (6) · Status Epilepticus (6)
Nervous System Diseases (347) · Central Nervous System Diseases (346) · Brain Diseases (342) · Pathological Conditions, Signs and Symptoms (143) · Signs and Symptoms (140) · Neurologic Manifestations (137) · Epileptic Syndromes (73) · Epilepsy, Generalized (59) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Genetic Diseases, Inborn (33) · Mental Disorders (11) · Pathologic Processes (11) · Headache Disorders (10) · Headache Disorders, Primary (10)
Levetiracetam (41) · Lacosamide (26) · brivaracetam (25) · Topiramate (17) · Cannabidiol (16) · Pregabalin (15) · Lamotrigine (13) · eslicarbazepine acetate (12) · Fenfluramine (9) · ezogabine (9) · Zonisamide (8) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (7) · Valproic Acid (7) · rufinamide (6) · 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (5)
UCB Pharma (34) · GlaxoSmithKline (18) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (14) · Eisai Inc. (13) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (11) · UCB BIOSCIENCES, Inc. (11) · UCB Pharma SA (11) · UCB Japan Co. Ltd. (10) · Jazz Pharmaceuticals (9) · SK Life Science, Inc. (9) · UCB Biopharma SRL (9) · Bial - Portela C S.A. (8) · Lady Hardinge Medical College (7) · Pfizer (7) · UCB Biopharma S.P.R.L. (6)
United States (175) · Germany (89) · Poland (87) · France (86) · Spain (80) · Italy (77) · Canada (63) · Australia (62) · Belgium (62) · Hungary (57) · Japan (52) · Russia (51) · United Kingdom (51) · Czechia (47) · Mexico (47)
Satinder Aneja, MD (4) · Barbara Bennett, PhD (3) · Eric H Kossoff, MD (3) · Neha Parikh (3) · Amit Ray, MD (2)
PMID 26899665, PMID 33825230, PMID 34218211, PMID 33461041, PMID 35285519, PMID 27265725, PMID 27335114, PMID 27589414, PMID 27608437, PMID 27988967, PMID 28004320, PMID 28236727, PMID 28279891, PMID 29414542, PMID 29908435, PMID 32432339, PMID 33338829, PMID 34155568, PMID 34768178, PMID 34870321, PMID 35582748, PMID 38788664, PMID 17283312, PMID 19327967, PMID 19863578, PMID 21095488, PMID 22512894, PMID 26471380, PMID 26666500, PMID 27683846, PMID 29363050, PMID 29486396, PMID 29768152, PMID 33142014, PMID 33179247, PMID 33540241, PMID 33780735, PMID 33797076, PMID 33942560, PMID 34033237, PMID 34246118, PMID 34265088, PMID 34265173, PMID 36410152, PMID 36435010, PMID 37052803, PMID 38462625, PMID 39648629, PMID 40775196, PMID 10227614
2014 (20), 2023 (8), 2004 (6), 2008 (6), 2015 (4), 2016 (4), 2009 (2), 2017 (2), 2018 (2), 2005 (1), 2019 (1), R01NS040808 (1), R01NS054805 (1), U01NS045803 (1)